Indivior (INDV)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$34.94+0.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · INDV
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $35 INDV trades at 9.6× p/e, below its 16× p/e peer median. Our $46 fair value sits well above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $43–$53. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $46.00 | — | — | Analyst | high |
| Peer EV/EBITDA | 12M | $7.38 | 8.9 | 1.07 | TTM | high |
| Peer P/E | 12M | $58.65 | 16.1 | 3.65 | TTM | high |
| Peer P/S | 12M | $31.19 | 2.9 | 10.73 | TTM | high |
| Own P/E history |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$43.00 – $53.00 (median $46.00) · 3 analysts · as of 2026-08-05
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $47.05 |
| 12.9 |
| 3.65 |
| TTM |
| high |
| triangulated | 12M | $64.79 | 16.1 | 4.03 | Triangulated | high |
| Peer P/S | 3Y | $32.75 | 2.9 | 11.27 | guidance | medium |
| Peer P/S | 5Y | $32.70 | 2.9 | 11.25 | guidance | medium |